---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-027629"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2024-02-08T23:59:59+00:00"
generated_at: "2026-06-06T05:45:04.484312+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Acrivon Therapeutics appoints Ivana Magovcevic-Liebisch, Ph.D., J.D., to board of directors

## Summary
- Appointment effective February 8, 2024; she will receive 32,500 stock options vesting over 3 years.
- Dr. Magovcevic-Liebisch is President and CEO of Vigil Neuroscience and brings 25+ years of industry experience.
- She will enter into standard indemnification agreement and receive cash compensation per non-employee director policy.
- No arrangements or transactions requiring disclosure under Item 404(a) exist with her selection.

## SEC filing metadata
- accession: 0001193125-24-027629
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2024-02-08T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000119312524027629/0001193125-24-027629-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000119312524027629/d750834d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-027629
- JSON: https://secwatch.observer/filing/0001193125-24-027629.json
- Plain text: https://secwatch.observer/filing/0001193125-24-027629.txt

## Key facts
- Executive change
  Ivana Magovcevic-Liebisch was appointed as Director at Acrivon Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On February 7, 2024, the Board of Directors of Acrivon Therapeutics, Inc. (the “Company”) appointed Ivana Magovcevic-Liebisch, Ph.D., J.D., as a director of the Company, effective February 8, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781174/000119312524027629/0001193125-24-027629-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.